Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO)

Price$3.86

Value ScoreD

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-32.80%

Price vs S&P 500 (4W)-7.44%

VGM Score47.70

Market Capitalization$234.13M

All Metrics

Book Value / Share (Quarterly)$0.87

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)111.68%

Cash Flow / Share (Quarterly)$-0.94

Price vs S&P 500 (YTD)-17.17%

Gross Margin (TTM)99.46%

Net Profit Margin (TTM)-166.75%

EPS (TTM)$-1.13

10-Day Avg Trading Volume0.24M

EPS Excl Extra (TTM)$-1.13

Revenue Growth (5Y)42.49%

EPS (Annual)$-1.10

ROI (Annual)-67.87%

Gross Margin (Annual)99.43%

Net Profit Margin (5Y Avg)-1115.45%

Cash / Share (Quarterly)$1.61

Revenue Growth QoQ (YoY)-87.33%

ROA (Last FY)-45.88%

Revenue Growth TTM (YoY)1033.89%

EBITD / Share (TTM)$-1.02

ROE (5Y Avg)-227.70%

Operating Margin (TTM)-167.96%

Cash Flow / Share (Annual)$-0.87

P/B Ratio4.59x

P/B Ratio (Quarterly)4.88x

Net Income / Employee (Annual)$-612,800

EV / Revenue (TTM)6.73x

Net Interest Coverage (TTM)-57.95x

ROA (TTM)-60.10%

EPS Incl Extra (Annual)$-1.10

Current Ratio (Annual)6.45x

Quick Ratio (Quarterly)6.90x

3-Month Avg Trading Volume0.22M

52-Week Price Return23.73%

Revenue / Employee (TTM)$380,500

P/S Ratio (Annual)6.99x

Asset Turnover (Annual)0.29x

52-Week High$5.42

Operating Margin (5Y Avg)-1154.70%

EPS Excl Extra (Annual)$-1.10

CapEx CAGR (5Y)-1.96%

26-Week Price Return-19.21%

Quick Ratio (Annual)6.37x

13-Week Price Return-10.73%

Total Debt / Equity (Annual)0.23x

Current Ratio (Quarterly)7.03x

Enterprise Value$220.10M

Revenue / Share Growth (5Y)31.23%

Asset Turnover (TTM)0.36x

Revenue / Employee (Annual)$389,300

Inventory Turnover (Annual)0.79x

Pretax Margin (Annual)-157.40%

Cash / Share (Annual)$1.87

3-Month Return Std Dev52.54%

Gross Margin (5Y Avg)95.31%

Net Income / Employee (TTM)$-634,500

ROE (Last FY)-83.15%

Net Interest Coverage (Annual)-31.02x

EPS Basic Excl Extra (Annual)$-1.10

Receivables Turnover (TTM)378.31x

Total Debt / Equity (Quarterly)0.28x

EPS Incl Extra (TTM)$-1.13

Receivables Turnover (Annual)358.10x

ROI (TTM)-101.25%

P/S Ratio (TTM)7.15x

Pretax Margin (5Y Avg)-1115.45%

Revenue / Share (Annual)$0.70

Price vs S&P 500 (52W)-4.42%

Year-to-Date Return-5.78%

5-Day Price Return-1.01%

EPS Normalized (Annual)$-1.10

ROA (5Y Avg)-76.56%

Net Profit Margin (Annual)-157.40%

Month-to-Date Return0.00%

EBITD / Share (Annual)$-1.08

Operating Margin (Annual)-154.73%

LT Debt / Equity (Annual)0.23x

ROI (5Y Avg)-99.22%

LT Debt / Equity (Quarterly)0.28x

EPS Basic Excl Extra (TTM)$-1.13

P/B Ratio (Annual)3.70x

Inventory Turnover (TTM)0.86x

Pretax Margin (TTM)-166.75%

Book Value / Share (Annual)$1.11

Price vs S&P 500 (13W)-21.39%

Beta0.52x

Revenue / Share (TTM)$0.52

ROE (TTM)-137.82%

52-Week Low$2.20

vGradeD

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.33est. -0.44

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.07

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
OBIOOrchestra BioMed Holdings, Inc. Ordinary Shares	D	B	C	$3.86
SYKStryker Corporation	C	C	D	$295.00
MMM3M Company	C	F	C	$151.65
BSXBoston Scientific Corp.	C	B	F	$47.69
BDXBecton, Dickinson and Co.	B	C	C	$145.61
MDLNMedline Inc. Class A common stock	B	D	D	$34.47
DXCMDexCom, Inc.	C	B	C	$72.77
RMDResMed Inc.	B	B	D	$186.46
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.31
SOLVSolventum Corporation	C	D	C	$78.36
PENPenumbra, Inc.	F	C	C	$319.37

About

Orchestra BioMed Holdings Inc is a biomedical company that develops innovative medical device technologies through strategic partnerships with established device manufacturers. The company's flagship products include BackBeat Cardiac Neuromodulation Therapy for treating hypertension and Virtue Sirolimus AngioInflusionBalloon for treating atherosclerotic artery disease. Its partnership-enabled model reduces development risk by sharing the burden with commercialization partners while accelerating time to market for its product candidates.